trending $BIOC $HMNY Recommendation 1.7 Buy
Biocept might need to be added to the dictionary as an example of stock volatility. The company’s share-price swings up and down are almost dizzying. Does the news about Biocept’s agreement with Alliance Global FZ merit such a major move? Probably not.
This deal is only the latest of eight international distribution agreements for Biocept’s Target Selector liquid biopsy tests. These tests are used to detect cancer biomarkers in circulating tumor DNA (ctDNA) or on circulating tumor cells (CTCs) in blood samples. Gaining access to new markets for the Target Selector tests is a positive for Biocept, but it’s not such good news that the stock should skyrocket.
The hard truth is that the countries where Alliance Global FZ will distribute Biocept’s products aren’t exactly major markets. Only one country was specifically named in Biocept’s press release — the United Arab Emirates (UAE). The population of the UAE is less than 10 million. Granted, there are other countries in the region to which Alliance Global FZ will distribute Target Selector liquid biopsies, but this deal isn’t a game changer for Biocept(fool com)
|Earnings Estimate||Current Qtr. (Jun 2018)||Next Qtr. (Sep 2018)||Current Year (2018)||Next Year (2019)|
|No. of Analysts||2||2||2||2|
|Year Ago EPS||N/A||-5.79||-17.46||-3.54|
Now what trending $BIOC $HMNY
Investors should probably expect continued extreme volatility for Biocept stock in the coming months. The company is losing money to the tune of $5.7 million or more every quarter. Biocept is running out of cash, a fact that prompted the rights offering announced on Thursday.
Until Biocept is able to demonstrate that it’s on a clear path to profitability and growth, my view is that investors are better off staying away from the stock. The distribution deal with Alliance Global FZ could help the company move in the right direction, but there’s a long way to go.
Biocept is not on our top “Buy” list, but these 10 stocks are
Investing geniuses David and Tom Gardner just released their best stocks to buy now — and it could pay to listen. Especially when you consider their average stock pick is up 353% vs. a mere 81% for the S&P 500.
|Revenue Estimate||Current Qtr. (Jun 2018)||Next Qtr. (Sep 2018)||Current Year (2018)||Next Year (2019)|
|No. of Analysts||2||2||2||2|
|Year Ago Sales||N/A||1.17M||20.88M||340.62M|
|Sales Growth (year/est)||N/A||7,936.70%||1,531.10%||88.20%|
|Earnings History||Invalid Date||9/29/2017||12/30/2017||3/30/2018|
|EPS Trend||Current Qtr. (Jun 2018)||Next Qtr. (Sep 2018)||Current Year (2018)||Next Year (2019)|
|7 Days Ago||-0.95||-0.54||-3.54||-0.14|
|30 Days Ago||-0.95||-0.54||-3.54||-0.14|
|60 Days Ago||-0.98||-0.96||-4||-1.79|
|90 Days Ago||-0.98||-0.96||-4||-1.79|
|EPS Revisions||Current Qtr. (Jun 2018)||Next Qtr. (Sep 2018)||Current Year (2018)||Next Year (2019)|
|Up Last 7 Days||N/A||N/A||N/A||N/A|
|Up Last 30 Days||N/A||N/A||N/A||N/A|
|Down Last 7 Days||N/A||N/A||N/A||N/A|
|Down Last 30 Days||N/A||N/A||N/A||N/A|
|Growth Estimates||HMNY||Industry||Sector||S&P 500|
|Next 5 Years (per annum)||N/A||N/A||N/A||0.11|
|Past 5 Years (per annum)||-4.44%||N/A||N/A||N/A|